The phase 3 clinical trial of the first antidote against COVID, VINCOV-19, is expected to begin soon as the drug is ready for market authorization. VINCOV-19 is a joint effort of the University of Hyderabad (UoH), the Centre for Cellular and Molecular Biology (CCMB) and VINS Bioproducts Limited.
The phase 2 clinical trial of the drug in over 200 participants was done in September 2022. "Phase 2 Clinical Trials were conducted across multiple centres in India and included over 200 patients. The Phase 2 Clinical Trials also included testing the antidote against the Omicron variant to ensure maximum coverage against the virus and its known mutations," says an official statement from UoH emphasizing on the need to tackle the Omicron variant.
